Takeda’s Entyvio (vedolizumab) Receives NMPA’s Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn’s Disease

Takeda’s Entyvio (vedolizumab) Receives NMPA’s Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease

Shots:

  • The NMPA has approved Entyvio to treat patients with moderately to severely active UC & CD having inadequate response to, lost response to, or were intolerant to conventional therapies or TNFα inhibitors
  • In 2018, NMPA has included the therapy in the first batch list of ‘urgently needed’ overseas medicines for accelerated approval
  • Entyvio (IV) is a gut-selective mAb, designed to specifically antagonize the α4β7 integrin to intestinal (MAdCAM-1) but not VCAM-1 and has received marketing authorization in 60+ countries including the US and EU

Click here to­ read full press release/ article | Ref: Takeda | Image: Pinterest